Zai Lab Limited ZLAB
At closeNov 5, 2026, 4:01 AM EST
Pre-market · Nov 5, 4:01 AM ET
- YTD
- +29.25%
- 1 year
- -11.94%
- Market cap
- 2.83B
- Revenue (ttm)
- 449.61M
- Profit margin
- -41.86%
- EPS (ttm)
- -1.70
- Shares out
- 124.15M
- Forward P/E
- -10.88
- YTD return
- +29.25%
- 1-year return
- -11.94%
- Volume
- 806.15K
- Avg volume
- 1.08M
- Open
- 23.17
- Previous close
- 21.96
- Day's range
- 22.52 – 23.40
- 52-week range
- 15.96 – 27.50
- Beta
- 0.72
- Analysts
- Strong Buy
- Price target
- 33.48 (+46.8%)
- Earnings date
- Nov 5, 2026
5D -1.16 (-5.00%)
Key statistics
- Enterprise value
- 2.10B
- PEG ratio
- 0.00
- Price / sales
- 6.30
- Price / book
- 4.22
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -3.30%
- Free cash flow
- -83.96M
- Total cash
- 617.52M
- Total debt
- 254.58M
- Return on equity
- -26.91%
- Short % of float
- 8.00%
- 50-day average
- 24.78
- 200-day average
- 21.01
Analyst view
Consensus: strong buy
- Target (low)
- 24.25
- Target (mean)
- 33.48
- Target (high)
- 50.00
- Strong buy2
- Buy8
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 5, 2026
Expected Nov 5, 2026. Consensus EPS estimate -0.59177.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2026 | Sep 30, 2026 | -0.59177 | — | — | — |
| Aug 6, 2026 | Jun 30, 2026 | -0.67939 | -0.46 | +0.22 | +32.29% |
| May 7, 2026 | Mar 31, 2026 | -0.52616 | -0.46 | +0.07 | +12.57% |
| Feb 26, 2026 | Dec 31, 2025 | -0.44 | -0.46 | -0.02 | -4.55% |
| Nov 6, 2025 | Sep 30, 2025 | -0.28 | -0.33 | -0.05 | -17.86% |
| Aug 7, 2025 | Jun 30, 2025 | -0.37 | -0.37 | 0.00 | 0.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 7, 2026 | Citigroup | main | Buy | Buy |
| May 8, 2026 | Citigroup | main | Buy | Buy |
| Mar 18, 2026 | JP Morgan | main | Overweight | Overweight |
| Feb 27, 2026 | Cantor Fitzgerald | main | Overweight | Overweight |
| Feb 5, 2026 | JP Morgan | main | Overweight | Overweight |
| Jan 7, 2026 | UBS | init | — | Buy |
About Zai Lab Limited
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company has a strategic collaboration with Tesaro, Inc., NovoCure Ltd., Deciphera Pharmaceuticals, LLC, Paratek Bermuda Ltd., argent BV, Turning Point Therapeutics, Inc., Entasis Therapeutics Holdings Inc., Karuna Therapeutics, Inc., Pfizer Inc., Amgen Inc., and with Boehringer Ingelheim GmbH. The company was incorporated in 2013 and is based in Pudong, China.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- China
- Website
- zailaboratory.com
News
Zai Lab Limited (ZLAB) Discusses Phase 1 Study Results of DLL3-Targeted ADC ZL-1310 in Small Cell Lung Cancer Transcript 
Zai Lab's Zoci Shows 82% Response Rate in Early Lung Cancer Study 
Zai Lab Announces Phase 1b Zoci Plus Atezolizumab Trial Delivers 81.8% Response Rate In First-Line Extensive-Stage Small Cell Lung Cancer, Advances Toward Phase 3 
Zai Lab's Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung Cancer 
Zai Lab Announces $250 Million Private Placement 
Zai Lab to Announce Third Quarter 2026 Financial Results and Recent Corporate Updates on November 5, 2026 
Zai Lab Limited Unsponsored ADR (ZLAB) – What Are Brokerages Thinking About This Stock? 
Zai Lab to Present Data From First Clinical Trial Evaluating ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, for Atopic Diseases 
Janux Therapeutics (NASDAQ:JANX) and Zai Lab (NASDAQ:ZLAB) Head-To-Head Survey 
Analyzing Zai Lab (NASDAQ:ZLAB) and Cytokinetics (NASDAQ:CYTK)
Your note
Sign in to keep a note on ZLAB — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AMADO RAFAEL | President | Sale | Apr 5, 2026 | 57,022 |
| DIEKMAN JOHN DAVID | Director | Stock Award(Grant) | Jun 16, 2026 | 122,140 |
| DU YING SAMANTHA | Chief Executive Officer | Conversion of Exercise of derivative security | Jul 1, 2026 | 1,221,400 |
| GAYNOR RICHARD BRIAN M.D. | Director | Purchase | Jun 30, 2026 | 80,737 |
| LEUNG NISA BERNICE WING-YU | Director | Stock Award(Grant) | Jun 16, 2026 | 96,297 |
| MOULDER LEON OLIVER JR. | Director | Stock Award(Grant) | Jun 16, 2026 | 94,973 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| RTW Investments LP | 5.78% | 6,574,032 | 149.89M | Jun 29, 2026 |
| TCG Crossover Management, LLC | 5.39% | 6,137,627 | 139.94M | Jun 29, 2026 |
| RA Capital Management, L.P. | 5.05% | 5,743,533 | 130.95M | Jun 29, 2026 |
| Adar1 Capital Management, LLC | 2.96% | 3,369,034 | 76.81M | Jun 29, 2026 |
| FMR, LLC | 2.47% | 2,815,214 | 64.19M | Jun 29, 2026 |
| Goldman Sachs Group Inc | 2.03% | 2,315,480 | 52.79M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| BARON SELECT FUNDS-Baron Emerging Markets Fund | 1.20% | 1,370,904 | 31.26M | Jun 29, 2026 |
| iShares Trust-iShares Biotechnology ETF | 0.65% | 740,494 | 16.88M | Sep 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 0.29% | 331,780 | 7.56M | Aug 30, 2026 |
| abrdn World Healthcare Fund | 0.27% | 311,294 | 7.10M | Jun 29, 2026 |
| Tema ETF Trust-Tema Oncology ETF | 0.14% | 161,278 | 3.68M | Aug 30, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund | 0.12% | 132,344 | 3.02M | Aug 30, 2026 |